Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

EOC to Start China Trial of Novel Immunotherapy for Breast Cancer

publication date: Dec 10, 2020

EOC Pharma, a Shanghai oncology company, announced approval to start a China Phase II trial of a novel immunotherapy for patients with metastatic breast cancer. EOC in-licensed China rights to EOC202 (eftilagimod alpha) from Immutep of Australia. Efti, a soluble LAG-3 fusion protein (LAG-3Ig), is a novel antigen presenting cell (APC) activator being tested in cancer and infectious disease. It will be administered in combination with paclitaxel. EOC was spun out of China in-licensing company Eddingpharm in 2015. More details....

Stock Symbols: (ASX: IMM; NSDQ: IMMP)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming event
Shanghai and Digital
May 10-14, 2021
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
The Ritz-Carlton Shanghai Pudong
March 23-25, 2021